Últimos Artículos de Diabetes, Obesity and Metabolism
- Effects of Intensive Blood Pressure Lowering in Patients with Diabetes: A Pooled Analysis of the STEP and ACCORD‐BP Randomized Trials
- A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
- Efficacy and Safety of Janagliflozin as Add‐on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double‐blind, Placebo‐controlled, Phase 3 Trial
- Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus
- Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
- Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results
- Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis
- Oral insulin (ORMD‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study
- A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol
- Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease – analyses from VERTIS CV, a randomized trial of the SGLT2 inhibitor ertugliflozin
- Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi‐ethnic population: Results from the Dallas Heart Study
- Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo
- Safety and Efficacy of an Oral Insulin (Capsulin) in Patients with Early‐Stage Type 2 Diabetes: A Dose‐Ranging Phase IIb Study
- Medical and surgical treatment of postbariatric hypoglycemia: retrospective data from daily practice
- Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial
- Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs, and mortality
- Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
- Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
- A simplified straightforward protocol for the use of U‐500 regular insulin
- Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects